Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 5 records in total 5
    records per page




    A Comprehensive Study on Prediction Reliability of The Severity of Computed Tomography Involvement in Patients with Covid-19 MESHD

    Authors: Semih Kalkan; Volkan Gurler; AHMET Guner; Macit Kalcik; Kamber Kasali; Mustafa Ferhat Keten; Gokhan Tonkaz; Emrah Bayam; Ahmet Karaduman; Mehmet Ozkan

    doi:10.21203/rs.3.rs-278630/v1 Date: 2021-02-26 Source: ResearchSquare

    Purpose: Computed tomography (CT) emerges as a high–sensitivity tool in diagnosing SARS-CoV-2 virus on admission, even with the cases of negative reverse transcription polymerase chain reaction (RT-PCR). Moreover, CT plays a significant role in the evaluation of disease severity. In this study, we aimed to identify several parameters that could aid in evaluating the initial chest CT severity score (CT-SS).Methods: A total of 348 RT-PCR positive patients were divided into three groups by evaluating the chest CT severity score (CT-SS) in detail. These three groups were defined as the CT-SS obtained 0-7, 8-15, 16-40 classified as mild, moderate and severe involvement, respectively. Patients with end-stage malignancy MESHD or immunodeficiency MESHD were excluded from the study. All CT images were evaluated by two chest radiologists, unaware of the clinical data.Results: The analysis of categorical variables show that the chest CT-SS tends to increase with higher CHA2DS2VASC risk score (RS) (p= 0.001), M-CHA2DS2VASC RS (p = 0.001), and CHADS2 RS (p = 0.003). Moreover, age, hypertension MESHD, cardiothoracic ratio, aortic diameter, white blood cell count, neutrophil counts, neutrophil-lymphocyte ratio, c-reactive protein HGNC, D-dimer, ferritin, fibrinogen HGNC, blood urea nitrogen, and lactate dehydrogenase were also found to be associated with higher chest CT-SS. A 5-variable multivariable linear regression model, consisting of more frequently used variables, suggests a higher CHA2DS2VASC RS as the only statistically significant variable predicting a higher severity scoreConclusion: The CHA2DS2VASC RS may assist clinicians in predicting the CT-SS in COVID-19 MESHD patients, even if they are asymptomatic.

    More severe hypercoagulation status, cytokine storm, and disease progression in coronavirus disease 2019 MESHD with persistent RT-PCR negative results: a multicenter prospective study

    Authors: Wei Du; Guochao Shi; Min Zhou; Yahui Liu; Gelei Lan; Xueqing Du; Chunrong Huang; Ranran Dai; Wei Chen

    doi:10.21203/rs.3.rs-85866/v1 Date: 2020-09-30 Source: ResearchSquare

    Purpose: Persistent negative results (at least 3 times) of reverse transcription–polymerase chain reaction (RT-PCR) from pharyngeal swabs are not rare in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients, but their characteristics have not yet been well studied.Methods: PCR confirmed, serum antibody confirmed with persistent negative PCR results, and clinically diagnosed patients hospitalized in two medical centers during February and March 2020 were included. Differences in clinical, imaging and laboratory characteristics as well as factors affecting their prognosis were analyzed.Results: There were 114 PCR confirmed, 17 serology confirmed and 21 clinically diagnosed patients included. Time from onset of disease to the first PCR and admission were similar among the groups. Compared with PCR-confirmed patients, serology-confirmed patients were older and likely to have hypertension MESHD, vomiting MESHD, or symptoms of chest pain MESHD and dyspnea MESHD. Regarding imaging manifestations, serology-confirmed patients were more prone to pleural effusion MESHD. In addition, higher levels of C-reactive protein HGNC, neutrophil-to-lymphocyte ratio, total bilirubin, D-dimer, fibrinogen HGNC, troponin, interleukin-6 HGNC and IL-8 HGNC were also found. Although with similar mortality, serology confirmed patients were more likely to have disease progression. High levels of D-dimer and IL-6 HGNC were possibly the underlying factors leading to their worse prognosis. On the other hand, clinically diagnosed patients were more similar to PCR-confirmed patients.Conclusion: Serology confirmed COVID-19 MESHD patients with at least three negative PCR results had different clinical characteristics and were likely to have disease progression, possibly due to more severe hypercoagulation status MESHD and cytokine storm.

    A Comprehensive Evaluation of Early Predictors of Disease Progression in Patients with COVID-19 MESHD: A Case Control Study

    Authors: Qiang Tang; Yanwei Liu; Yingfeng Fu; Ziyang Di; Kailiang Xu; Bo Tang; Hui Wu; Maojun Di

    doi:10.21203/rs.3.rs-50527/v1 Date: 2020-07-29 Source: ResearchSquare

    Background: The 2019 coronavirus disease MESHD ( COVID-19 MESHD) has become an unprecedented public health crisis with nearly 16 million confirmed cases and 630,000 deaths worldwide. Methods: We retrospectively investigated the demographic, clinical, laboratory, radiological and treatment data of COVID-19 MESHD patients consecutively enrolled from January 18 to May 15, 2020, in Taihe and Jinzhou central hospital. Results: Of all 197 patients, the median age was 66.5 years (IQR 7-76), and 120 (60.9%) patients were males. We identified 88 (44.7%) of 197 COVID-19 MESHD patients as the disease progression (aggravation) cases. The aggravation cases tend to have more medical comorbidity: hypertension MESHD (34.1%), diabetes MESHD (30.7%), and presented with dyspnea MESHD (34.1%), neutrophilia (60.2%), and lymphocytopenia MESHD (73.9%), compared with those without. And the patients with disease progression showed significantly higher level of Fibrinogen HGNC (Fbg), D-dimer, IL-6 HGNC, C-reactive protein HGNC ( CRP HGNC), procalcitonin (PCT), and serum ferritin, and were more prone to develop organ damage in the liver, kidney, and heart (P<0.05). Multivariable regression showed that advanced age, comorbidities, lymphopenia MESHD, and elevated level of Fbg, lactate dehydrogenase (LDH), Cardiac troponin ( CTnI HGNC), IL-6 HGNC, serum ferritin were the significant predictors of disease progression. Further, we investigated antibody responses to SARS-CoV-2 and found that the levels of IgM and IgG were significantly higher in the disease progression cases compared to non-progression cases from 3 weeks after symptom onset. In addition, the disease progression group tended to peak later and has a more vigorous IgM/IgG response against SARS-CoV-2. Further, we performed Kaplan-Meier analysis and found that 61.6% of patients had not experienced ICU transfer or survival from hospital within 25 days from admission.Conclusions: Investigating the potential factors of advanced age, comorbidities and elevated level of IL-6 HGNC, serum ferritin and Kaplan-Meier analysis enables early identification and management of patients with poor prognosis. Detection of the dynamic antibody may offer vital clinical information during the course of SARS-CoV-2 and provide prognostic value for patients infection.  

    Clinical characteristics and outcomes in diabetes patients admitted with COVID-19 MESHD in Dubai: a cross-sectional single centre study.

    Authors: Rahila Bhatti; Amar Omer; Samara Khattib; Seemin Shiraz; Glenn Matfin

    doi:10.1101/2020.07.08.20149096 Date: 2020-07-10 Source: medRxiv

    Aim: To describe the clinical characteristics and outcomes of hospitalised Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) patients with diabetes MESHD. Methods: A cross-sectional observational study was conducted in patients with diabetes MESHD admitted with COVID-19 MESHD to Mediclinic Parkview Hospital in Dubai, United Arab Emirates (UAE) from 30th March to 7th June 2020. They had laboratory and/or radiologically confirmed severe acute respiratory syndrome-coronavirus-2 MESHD (SARS-CoV-2), known as COVID-19 MESHD. Variation in characteristics, length of stay in hospital, diabetes MESHD status, comorbidities and outcomes were examined. Results: A total of 103 patients with confirmed COVID-19 MESHD presentations had diabetes MESHD. During the same timeframe, 410 patients overall were admitted with COVID-19 MESHD infection. This gives a total proportion of persons admitted with COVID-19 MESHD infection and coexistent diabetes MESHD/prediabetes of 25%. 67% (n=69) of the COVID-19 MESHD diabetes MESHD cohort were male. Patients admitted with COVID-19 MESHD and diabetes MESHD represented 17 different ethnicities. Of these, 59.2% (n=61) were Asians and 35% (n=36) were from Arab countries. Mean age (SD) was 54 (12.5) years. 85.4% (n=88) were known to have diabetes MESHD prior to admission, while 14.6% (n=15) were newly diagnosed with either diabetes MESHD or prediabetes MESHD during admission. Most patients in the study cohort had type 2 diabetes MESHD or prediabetes MESHD, with only 3% overall having type 1 diabetes MESHD (n=3). 46.9% of patients had evidence of good glycaemic control of their diabetes MESHD during the preceding 4-12 weeks prior to admission as defined arbitrarily by admission HbA1 HGNCc <7.5%. 73.8% (n=76) had other comorbidities including hypertension MESHD, ischaemic heart disease MESHD, and dyslipidaemia. Laboratory data Mean(SD) on admission for those who needed ward-based care versus those needing intensive care unit (ICU) care: Fibrinogen HGNC 462.75 (125.16) mg/dl vs 660 (187.58) mg/dl ; D-dimer 0.66 (0.55) mcg/ml vs 2.3 (3.48) mcg/ml; Ferritin 358.08 (442.05) mg/dl vs 1762.38 (2586.38) mg/dl; and CRP HGNC 33.9 (38.62) mg/L vs 137 (111.72) mg/L were all statistically significantly higher for the ICU cohort (p<0.05). Average length of stay in hospital was 14.55 days. 28.2% of patients needed ICU admission. 4.9% (n=5) overall died during hospitalisation (all in ICU). Conclusions: In this single-centre study in Dubai, 25% of patients admitted with COVID-19 MESHD also had diabetes MESHD/ prediabetes MESHD. Most diabetes MESHD patients admitted to hospital with COVID-19 MESHD disease were males of Asian origin. 14.6% had new diagnosis of diabetes MESHD/prediabetes on admission. The majority of patients with diabetes MESHD/ prediabetes MESHD and COVID-19 MESHD infection had other important comorbidities (n=76; 73.8%). Only 4 patients had negative COVID-19 MESHD RT-PCR but had pathognomonic changes of COVID-19 MESHD radiologically. Our comprehensive laboratory analysis revealed distinct abnormal patterns of biomarkers that are associated with poor prognosis: Fibrinogen HGNC, D-dimer, Ferritin and CRP HGNC levels were all statistically significantly higher (p<0.05) at presentation in patients who subsequently needed ICU care compared with those patients who remained ward-based. 28.2% overall needed ICU admission, out of which 5 patients died. More studies with larger sample sizes are needed to compare data of COVID-19 MESHD patients admitted with and without diabetes MESHD within the UAE region.

    Clinical characteristics and risk factors of patients with severe COVID-19 MESHD in Jiangsu province, China: a retrospective multicentre cohort study

    Authors: Songqiao Liu; Huanyuan Luo; Yuancheng Wang; Luis E. Cuevas; Duolao Wang; Shenghong Ju; Yi Yang

    doi:10.21203/rs.3.rs-23940/v2 Date: 2020-04-20 Source: ResearchSquare

    Background: Coronavirus Disease-2019 ( COVID-19 MESHD) has become a major health event that endangers people health throughout China and the world. Understanding the factors associated with COVID-19 MESHD disease severity could support the early identification of patients with high risk for disease progression, inform prevention and control activities, and potentially reduce mortality. This study aims to describe the characteristics of patients with COVID-19 MESHD and factors associated with severe or critically ill MESHD presentation.Methods: Multicentre retrospective cohort study of all individuals with confirmed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections MESHD diagnosed at 24 COVID-19 MESHD-designated hospitals in Jiangsu province between the 10th January and 15th March 2020. Demographic, clinical, laboratory, and radiological data were collected at hospital admission and data on disease severity were collected at from admission. Patients were categorised as asymptomatic/mild/moderate, and severe/critically ill according to the worst level of COVID-19 MESHD recorded during hospitalisation.Results: A total of 625 patients, 64 (10.2%) were severe/ critically ill MESHD and 561 (89.8%) were asymptomatic/mild/moderate. All patients were discharged and no patients died. Patients with severe/critically ill COVID-19 MESHD were more likely to be older, to be single onset (i.e. not to a cluster of cases in family/community), to have a medical history of hypertension MESHD and diabetes MESHD; had higher temperature, faster respiratory rates, lower peripheral capillary oxygen saturation (SpO2), and higher CT image quadrant scores and pulmonary opacity MESHD percentage; had increased C-reactive protein HGNC, fibrinogen HGNC, and D-dimer on admission; and had lower white blood cells, lymphocyte, and platelet counts and albumin on admission than asymptomatic/mild/moderate cases. Multivariable regression showed that odds of being a severe/critically ill case were associated with age (year) (OR 1.06, 95%CI 1.03-1.09), lymphocyte count (109/L) (OR 0.25, 95%CI 0.08-0.74), and pulmonary opacity MESHD in CT (per 5%) on admission (OR 1.31, 95%CI 1.15-1.51).Conclusions: Severe or critically ill MESHD patients with COVID-19 MESHD is about one-tenths of patients in Jiangsu. Age, lymphocyte count, and pulmonary opacity MESHD in CT on admission were associated with risk of severe or critically ill COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.